In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unum Therapeutics Inc.

www.unumrx.com

Latest From Unum Therapeutics Inc.

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.

Financing Business Strategies

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.

Financing Business Strategies

Appointments: Changes At Merck KGaA, Servier, Unum and Aduro

The latest biopharma industry appointments include a new chief patient officer at Servier, executives at Merck KGaA, Unum and Aduro, as well as several board updates.

Appointments BioPharmaceutical

IPO Is Next Finance Target For Hookipa Biotech After $60m Series C

Emerging Company Profile: Austria's privately-held Hookipa Biotech just raised $60m to progress two proof of concept clinical trials for its lead development programs. It will eventually seek a public listing.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Unum Therapeutics Inc.
  • Senior Management
  • Chuck Wilson, PhD, Pres. & CEO
    Matthew Osborne, CFO
    Seth Ettenberg, PhD, CSO
    Jessica Sachs, MD, CMO
  • Contact Info
  • Unum Therapeutics Inc.
    Phone: (617) 945-5576
    200 Cambridge Park Dr., Ste. 3100
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register